NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
June 8, 2023 in Presentations

ASCO 2023 Abstract: Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies

NanOlogy 0 Like Post Comments Off on ASCO 2023 Abstract: Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal